title: Bone marrow transplantation for hematological disorders--Shiraz experience.
abstract: OBJECTIVE
  In the past 8 years, 120 cases of hematological disorders were transplanted from the HLA identical donors.
  
  
  METHODS
  Using chemotherapy based conditioning regimen with cyclophosphamide 200 mg/kg and busulfan 15-16 mg/kg, 80 cases of beta-thalassemia major and 35 cases of leukemia and five patients with aplastic anemia had received bone marrow transplantation.
  
  
  RESULTS
  The five-year-survival in thalassemic group was 72%, for leukemic group (acute and chronic) was 58%, and also for aplastic anemia 65%. Transplantation related mortality was the cause of death in 29 cases. The two major causes of death were acute graft versus host disease and poor medical condition of patients before marrow transplantation.
  
  
  CONCLUSIONS
  At the present time, allogenic marrow transplantation is curative mode of treatment for many hematological diseases.
authors.affiliation: Shiraz University of Medical Sciences, Shiraz-Iran. nooranih@sums.ac.ir
authors.forename: Nourani H
authors.initials: NH
authors.lastname: Khojasteh
authors.forename: M
authors.initials: M
authors.lastname: Zakernia
authors.forename: M
authors.initials: M
authors.lastname: Ramzi
authors.forename: M
authors.initials: M
authors.lastname: Haghshenas
mesh_terms: D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D008297:Male; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000628:therapy*